Brief description: Researchers in the Department of Educational and Counseling Psychology at UAlbany are conducting a study about parent perspectives and experiences supporting a child with a disability and are looking for your participation! 

Learn more here 

Who is eligible: Parent of a child or young adult with a disability with culturally and ethnically diverse identities (e.g., race, ethnicity, ability, gender, socioeconomic status, sexual orientation, citizenship). 

Time involvement: The study consists of a 15-minute survey and optional 30-minute interview via Zoom or by phone. 

Compensation:You will not be paid for participating in this study.   

Contact Information: If you have questions, contact Elizabeth Slusarz at eslusarz@albany.edu or Dr. Tammy Ellis-Robinson at tellis-robinson@albany.edu.

Post Expires: 12/31/2023
 

Brief description: The purpose of this SSBC research study is to apply cutting-edge science to identify objective biological markers for schizophrenia, to advance our understanding of the illness, and identify potential novel treatments.

Learn more: https://www.youtube.com/watch?v=R4GEHQeCzzU

Who is eligible: If you are between the ages of 18 to 50 and have experienced psychotic-like symptoms such as:

• Unusual thoughts
• Suspiciousness
• Perceptual disturbances, like hearing things that others do not

Time involvement: Study visit at baseline and then every 6 months.

Compensation: Participants can receive up to a $ 2,000-a-year stipend.

Contact Information: If you’d like to participate,  please contact the Study Research Coordinator at 212-659-1674 or email ssbc@mssm.edu.

Post expires: 3/8/2023

Brief description: This study is for first-degree relatives (parents, children, siblings) of individuals with schizophrenia. The goal of the study is to learn about people’s understanding of and interest in psychiatric polygenic risk scores (PRS), a type of experimental genetic technology that may help predict the likelihood of developing certain psychiatric conditions and therefore inform personal decision-making related to risk. The PRS technology is not currently used in clinical settings but is being used in research settings in an exploratory fashion. All interviews will be conducted by January 31, 2023. Use this link to begin the 5 – 10 minute survey:

Who is eligible: Individuals may be eligible for this study if they are: 18-88 years of age, English-speaking and a first-degree relative of someone with schizophrenia (individuals with a personal diagnosis of schizophrenia are not eligible).

Time involvement: Participants will complete a 5-10 minute online survey and participate in a Zoom interview lasting up to 90 minutes.

Compensation: No compensation will be provided.

Contact Information: Please email Sara Rubovits, BS, Masters in Genetic Counseling Candidate University of Maryland School of Medicine, Sara.rubovits@som.umaryland.edu. if interested.

Post expires: 01/30/2022

Brief description: Participants will first complete a baseline research assessment including questionnaires, clinical interviews, providing a urine sample, and a week-long, in-home characterization of sleep duration and quality using a sleep diary and an actigraph (a small digital device worn on the wrist). Next, participants will complete two sleep assessments overnight in a sleep lab (e.g., polysomnography) using two sleep schedules: 1) an undisturbed sleep (8 hours); and 2) a restricted sleep (4 hours). As part of each of these overnight sleep assessments, participants will be connected to EEG equipment and complete memory tasks before going to sleep and after waking up, as well as provide blood and saliva samples. Finally, after each overnight sleep, participants will complete a 3-day assessment of “real-world” daily functioning including symptoms, mood, and emotion regulation using smartphones. Typically, the two overnight sleep assessments are scheduled 1-2 weeks apart, with the study participation usually completed within one month.  Additional information is available at: https://clinicaltrials.gov/ct2/show/NCT05032963?term=kimhy&draw=2&rank=1

Who is eligible: Individuals ages 18-50 who have a diagnosis of schizophrenia, schizoaffective, or schizophreniform disorder. Taking antipsychotic medication for >7 weeks and on current doses for 4 weeks.

Compensation: Yes – eligible participants may receive up to $320 for completion of all the study procedures, as well as $10 reimbursement of travel expenses for each research visit.

Post expires: 05/16/2024

Brief description: Researchers at the Icahn School of Medicine at Mount Sinai are interested in identifying biological markers for schizophrenia and related mental illnesses through the collection of mental health information, brain images, as well as blood and cerebrospinal fluid (CSF) from persons who have or have had psychotic-like experiences. Such experiences include unusual or odd thoughts or behavior, suspiciousness or paranoia, and/or perceptual disturbances, like hearing one’s name being called or seeing shadows out of the corner of the eye. This study does not offer treatment, but we will assist participants in finding treatment, if desired. This study is funded by the Broad Institute.

Who is eligible: Individuals ages 18-50 who have psychotic-like experiences, including individuals who have been diagnosed with schizophrenia, schizoaffective disorder, or schizophreniform (though this is not necessary).

Time involvement: This study consists of a baseline visit, and 6-month visit, and a 12-month visit, all of which include clinical questionnaires, cognitive testing, brain imaging, and a lumbar puncture.

Compensation: Participants will be compensated up to $2,250 for completing the study.

Contact Information: Please email clinical research coordinator Sophia Shuster at sophia.shuster@mssm.edu if interested.

Post expires: 09/15/2023

This study is a clinical research trial for the oral medication BI 1358894. The trial will determine if BI 1358894 is safe and effective in patients with Major Depressive Disorder (MDD) who have not responded to other forms of treatment. Participants will be randomly assigned to receive a certain dose of BI 1358894, a placebo, or quetiapine for a period of six weeks. Quetiapine is a medication that has been approved for patients in the United States and the European Union who have not responded to first line treatment of MDD. Participants will receive compensation for their time and travel.

This study is seeking 431 participants. Participants may be eligible for this study if they:

• Are between the ages of 18 and 65
• Have been diagnosed with Major Depressive Disorder
• Have engaged in documented ongoing treatment for depression with one method for at least six weeks

Please note that these criteria are not complete. Certain other factors, including other mental health diagnoses, may disqualify an individual from participation. For a full list of inclusion and exclusion criteria, please visit this site for more information.

The study will take place at approximately 86 trial centers in 11 countries. Twenty of these trial centers are located in the United States. For a full list of study locations, please visit this site.

If you have questions or would like more information, please contact the researchers at (800) 236-4236 or register to learn more here.

Researchers at Stevens Institute of Technology are conducting a study to understand cognitive impairment due to various mental illnesses such as depression and bipolar disorder. This study will collect information about participants’ facial behavior features using a privacy-preserving mobile application our group developed and use that and other collected information to attempt to model the severity of user depression and other mental illness. The app developed by the researchers extracts facial features from pictures taken of the participants. Only the features are transmitted to the researchers: never the images.

Eligible participants are between 18 and 25 years old and possess a smart phone with the latest version of Android 9 or higher installed on it.

Participants will be compensated $20 for a brief interview, survey, and installation of the app, as well as $25 per week for four weeks if they have >75% compliance, and possibly $15 more if selected for an exit interview (only those participants with >90% compliance are eligible.)

The study lead and primary contact is Mohammad Rahul Islam (mislam5@stevens.edu). The secondary contact is Simon Wagner (swagner2@stevens.edu).

For more information:  https://sites.google.com/view/hci-grace-bae/project/mobile-sensing-and-behavior-modeling-for-mental-health.

The study is funded by a non-profit grant from Stevens Institute of Technology and conducted by researchers from the Human-Computer Interaction Lab at Stevens Institute of Technology.

Post expires: January 2023

Do you provide care or support to someone diagnosed with schizophrenia? We are looking for secondary informants – this would be professionals who work with people with schizophrenia.*

Would you like to share your general observations regarding cognitive problems (e.g., problems with thinking, memory) that patients with schizophrenia might experience?

What Does the Study Involve?

As part of this study, we would ask you to:

• share with us your observations regarding cognitive problems that patients with schizophrenia might have e.g., whether the patient experiences any problems with remembering names, phone numbers or being able to read a book or pay attention to a movie or a book
• evaluate a questionnaire called the Schizophrenia Cognition Rating Scale (SCoRS) that is used by doctors to interview caregivers about cognitive problems that patients with schizophrenia might have; this scale consists of 22 questions related to cognitive problems, and we would like to ask whether you think that each of these questions on the scale is relevant and easy to understand

How Long Does the Study Take?

This study consists of one 90-minute interview conducted remotely via a communication platform (e.g., MS Teams, Skype, Zoom, WebEx, RingCentral, GoToMeeting, Lifesize).

You will also receive reimbursement for your time.

If you are interested in participating in our study, please email SCoRSresearch@parexel.com for more information.

* By secondary informants we mean individuals with formal training in working with patients with schizophrenia in outpatient and/or home settings, including but not limited to case manager or group home staff members, psychiatric social workers, social workers, psychiatric mental health nurses. Eligible individuals would be health or social health professionals who see a patient with schizophrenia for at least 1hr per week, face to face.

Researchers at the Icahn School of Medicine at Mount Sinai are interested in studying language patterns in people who have psychotic-like experiences. Such experiences include unusual or odd thoughts or behavior, suspiciousness or paranoia, and/or perceptual disturbances, like hearing one’s name being called or seeing shadows out of the corner of the eye. This study does not offer treatment, but we will assist participants in finding treatment, if desired.

Who is eligible: Individuals ages 15-40 who have psychotic-like experiences, including individuals who have schizophrenia or schizoaffective disorder (though this is not necessary).

Time involvement: This study consists of approximately two visits in which participants will complete clinical interviews and a videotaped open-ended interview. These visits can be completed via telehealth.

Compensation: Participants will be compensated $90 for completing the study.

Contact Information: Please email Dr. Shaynna Herrera at shaynna.herrera@mssm.edu if interested.

Post expires: 01/15/2023

This study aims to further understand family dynamics and experiences when a young person in the family starts to experience psychosis, from before the time period diagnosis until the current day. Participants will be asked to participate in two to three online interviews (about an hour in length) and participants will receive monetary compensation of $40 dollars at the end of each interview. Participants from the same family will be interviewed first together and then separately.

Participants must be at least 18 years of age, have a family member that experienced their first episode in the past 3-5 years with a schizophrenia spectrum disorder diagnosis (such as schizophrenia, schizoaffective disorder, schizophreniform disorder). The participant and at least one other family member should be willing to interview together and then separately about their experiences.

Contact: Cassandra Seltman, LCSW, principle investigator: cseltman@gradcenter.cuny.edu, (917) 656-6366 – call or text

Post Expiration: 1 year

Researchers at the Icahn School of Medicine at Mount Sinai are looking for adults with Post- traumatic Stress Disorder to participate in a brain imaging study. Study investigators hope to learn how the brain is affected by stress and anxiety using new brain imaging technology.

You may be eligible to participate in this study if you:

• Are 18-65 years old
• Have Post-traumatic Stress Disorder (PTSD)

Participation in this research study includes a study screen and brain scan using magnetic resonance imaging (MRI), which can be done over 1-3 visits. Each study visit is expected to last approximately 2 – 5 hours in length. Subjects will be compensated for their participation.

If you are interested in participating, please take our online pre-screen at https://redcap.mountsinai.org/redcap/surveys/?s=VionGV8Bjh

Post expires: 11/30/2022

This study is a clinical research trial for the investigational drug, BI 1358894. The trial will determine if the investigational drug is safe and effective for reducing symptoms of PTSD. Participants will be randomly assigned to receive either the oral investigational drug or placebo over a period of eight weeks. The goal of this study is to increase treatment options available for people experiencing PTSD.

Individuals may be eligible for this study if they:

• Are aged 18-65 and diagnosed with PTSD as primary psychiatric diagnosis
• Experienced the traumatic event at least 3 months before the screening visit
• Have never met diagnostic criteria for schizophrenia, schizoaffective disorder, schizophreniform disorder, bipolar disorder, delusional disorder, brief psychotic disorder, or any other psychotic disorder, as well as MDD with psychotic features

Individuals are not eligible for this study if they:

• Have a positive urine drug screen at the screening visit and are not willing to abstain (quit) from using marijuana [cannabis] for the duration of the study

There will be about 300 people with PTSD participating in this study worldwide. Total participation time is approximately 16 weeks, including screening, treatment, and follow-up. Participants may receive reimbursement for travel expenses and additional compensation may apply.

There are multiple study sites located across the U.S. For a list of study site locations, please visit the study website: www.ptsd-nami.com. If you have questions or would like more information, please refer to that same study website.

Dear Bipolar Caregivers,

WE NEED YOUR HELP.

We all know that the highs and lows and ups and downs of your loved ones can be hard, really hard – the worry, the fear, the uncertainty, you wanting to help, but not knowing how to. It was true for me and my caregiver. I like to say that I live with bipolar, but my loved one does too. He is critical to me and my well-being. He notices my symptoms before I do. He’s my first line of defense in addressing things before they escalate.

I think bipolar caregivers need more credit for the difficult role they play. I want to help caregivers, so I teamed up with a leading bipolar global scholar – Professor Gordon Parker at the University of New South Wales (UNSW) – to identify and analyze your concerns. We want to better understand the support you need and what would be helpful. We are hoping that through the power of shared lived experience and academic study, we can increase awareness of the support needs required to improve the lives of people living with bipolar and their caregivers.

We’re surveying bipolar caregiver needs. If you wish to participate, you can just click on the link below. It’s anonymous too. We promise to try to call much more needed attention to your needs. We are hoping to provide insights that could help people living with bipolar and their families reach recovery together. When families work together, bipolar does not stand a chance against us.

Learn more about our study and take care survey here:  https://www.forlikeminds.com/bipolar_caregiver_survey

A heartfelt thanks to you,
Katherine Ponte, BA, JD, MBA, CPRP
Faculty Member, Yale University
Board Member, NAMI-NYC
Living in recovery from severe bipolar I disorder

This survey is open until it receives 200 responses.

We are interested in understanding how stressful life events impact transgender and gender diverse (TGD) people. The purpose of this research is to promote trauma recovery for trans and gender diverse people by better understanding how discrimination blocks pathways to healing.

What you’ll be asked to do:

• Participate in 4 Zoom interview sessions scheduled over 1 year
• Provide saliva samples, complete several questionnaires, and participate in a structured interview
• Complete daily surveys for 14 days after each session

You may be eligible if you:

• Are between 18-65 years old
• Identify as transgender or gender diverse
• Have recently experienced a very stressful life event
• Currently live in New York City

Compensation: Eligible participants may earn up to $360 paid in gift cards.

• $50 for baseline session
• $60 for 3-month follow-up
• $80 for 6-month follow-up
• $110 for 12-month follow-up
• Up to an additional $20 for each 14-day daily survey period (total of up to an additional $60)

If you are interested in participating, please complete this online screening survey: https://tinyurl.com/y4pac7mw

For more information about this study, please contact our team at: BerkeLabTGD@gmail.com

For more information about our research team at the Gender-Based Violence Lab: https://www.berkelaboratory.com/

Post expires: June 30, 2023

The purpose of this SSBC research study is to apply cutting-edge science to identify objective biological markers for schizophrenia, to advance our understanding of the illness, and identify potential novel treatments.

Participants in this study will complete questionnaires about life experiences and medical history, undergo brain imaging, and collection of blood and cerebrospinal fluid (CSF) via lumbar puncture.

Click here to watch a video with more information.

If you are between the ages of 18 to 50 and interested in learning more about this schizophrenia research study, or if you’d like to participate, please contact the SSBC study site at Mount Sinai (New York, NY) by phone, 212-659-1974, or email ssbc@mssm.edu.

Study participants will be compensated for their time and travel expenses.

Expires: March 2023

NYU Langone Health OCD Research Study

We are looking for individuals with Obsessive-Compulsive Disorder (OCD) for our study at NYU Langone Health! The purpose of this study is to look at clinical symptoms, behavior, and brain function in the disorder.

You must:
• Be 18-55 years old
• Be medically healthy
• Have OCD

What would you have to do?
• Some questionnaires about your health and emotions
• Some computer tasks while having your brain activity measured with functional magnetic resonance imaging (fMRI)

Total participation time is 6 to 12 hours over 1 to 3 visits (some may be done remotely) and pays at a rate of $25 per hour.

If you want us to contact you to tell you more about the study, please fill out our study interest form: https://redcap.link/PNCLab

For more information, call the Psychiatric Neurocognition Laboratory at 212-404-3919, email us at pnclab@nyumc.org or visit us at psychneurocoglab.com. Please do not disclose any personal or sensitive information via email.

Post expires: November 2026

This is a 12-week study of levetiracetam added to a second-generation antipsychotic in early psychosis patients who have been ill for less than 5 years and continue to experience psychotic symptoms (delusions and/or hallucinations) despite at least 8 weeks of antipsychotic treatment. Levetiracetam (Keppra) is an FDA-approved medication for the treatment of epilepsy; it reduces excessive activity in the brain. This study will test the hypothesis that adding levetiracetam will improve psychotic symptoms that are unresponsive to antipsychotic treatment and will protect the brain from atrophy (volume loss). All subjects will receive a comprehensive psychiatric and medical evaluation by Dr. Goff as part of participation.

Participants will complete screening and baseline visits before being randomized to levetiracetam or placebo twice daily added to a second-generation antipsychotic prescribed by their psychiatric provider. They will complete weekly study visits for the first 4 weeks (Baseline, Weeks 2-4), and then attend visits at weeks 6, 8, and 12. Participants will be studied both by assessing change in symptom severity and cognitive performance over the 12 weeks, as well as using an imaging measure of hippocampal volume integrity at baseline and week 12. After completing week 12, participants will taper and stop the levetiracetam or placebo over 9 days.

To be eligible for this study, you must be:

• 16-40 years old
• Experienced a first episode of psychosis within the past 5 years, and have a diagnosis of schizophrenia, schizoaffective disorder, or schizophreniform disorder
• Have taken antipsychotic medication for a minimum of 8 weeks, and at a stable dose for at least 4 weeks
• Experiencing psychotic symptoms (delusions and/or hallucinations) despite antipsychotic treatment

Participants can receive up to $495.00 for completion of the study. Payments will be via cash or check.

• $25 for Screening (Visit 1)
• $75 for Baseline (Visit 2)
• $25 for Weeks 2,3,4,8
• $50 for Week 6
• $85 for Week 12
• $15 for Follow-up visit post tapering regimen
• There are also additional optional assessments participants can receive payment for

Have questions? Contact info and websites for more information:

• Fumika Ando, 917-628-0552, Fumika.ando@nyulangone.org
• https://med.nyu.edu/departments-institutes/psychiatry/research/schizophrenia
• https://clinicaltrials.gov/ct2/show/NCT04317807?term=Levetiracetam+in+Early+Psychosis&draw=2&rank=2

Post expires: October 2023

Researchers at the Icahn School of Medicine at Mount Sinai are looking for adults with Panic Disorder to participate in a brain imaging study. Study investigators hope to learn how the brain is affected by stress and anxiety using new brain imaging technology.

You may be eligible to participate in this study if you:

• Are 18-55 years old
• Have Panic Disorder (PD)

Participation in this research study includes a study screen and brain scan using magnetic resonance imaging (MRI), which can be done over 1-3 visits. Each study visit is expected to last approximately 2 – 5 hours in length. Subjects will be compensated for their participation.

If you are interested in participating, please take the online pre-screen here.

Contact: Vicki Soogrim at the Depression and Anxiety Center at vicki.soogrim@mssm.edu or 212-585-4621, or visit icahn.mssm.edu/research/depression-anxiety-center for more information.

Post expires: 12/31/2022

This study is an anonymous online survey for public safety personnel. The goal of this study is to better understand the effects of work-related stress and traumatic events on the well-being of public safety professionals. The survey will also explore the coping mechanisms and stress management techniques used by public safety personnel to inform the creation of more effective prevention programs and intervention strategies.

The survey is being conducted by researchers at the U.S. Marshals Service; Fairfax County, Virginia Police Department; and Nova Southeastern University.

Participants may be eligible for this study if they are:

• 18 years and older
• Active federal, state, local, or tribal law enforcement, corrections, fire and rescue, emergency medical services, or public safety communications personnel
• Military service members or veterans who currently serve in a public safety role

Total participation time is 30-40 minutes. Participation must be coordinated through your work agency/organization. Please see attached National Survey Invitation for details.

The survey will take place online. Participants will receive a unique link to complete the survey.

If you have questions or would like more information, please contact the United States Marshals Service, Behavioral Analysis Unit at USMS.BAU@usdoj.gov or the Fairfax County Police Department at FCPDNationalSurvey@fairfaxcounty.gov.

These documents have additional information about the study.

National Survey Invitation and National Wellness Survey Instrument Overview.

We are recruiting individuals into our observational study targeting tobacco using individuals with behavioral health disorders.

The Tobacco Harm Research Project participant must be:

• An adult (21 years or older) AND
• Currently or formerly a client of a public mental health or substance use service AND
• Currently a smoker AND
• Interested in changing their tobacco use AND
• NOT currently enrolled in another tobacco intervention program

For more information and to sign up, go to the Tobacco Harm Research Project website.

This post active through the Fall of 2022.

Interested in participating in an OCD study with your sibling?

We are looking for individuals with Obsessive-Compulsive Disorder and their siblings for our study investigating family risk at NYU Langone Medical Center!

You must:

• Be 18-60 years old
• Be medically healthy
• Have OCD OR have a sibling with OCD

What would you have to do?

• Some questionnaires about your health and emotions
• Some computer tasks while having your brain activity measured with functional magnetic resonance imaging (fMRI)

Total participation time is 4 to 10 hours over 1 to 3 visits and pays at a rate of $25 per hour.

If you want to be contacted to learn more about the study, please fill out the study interest form.

For more information, call the Psychiatric NeuroCognition Laboratory at 212-404-3919, email at pnclab@nyumc.org or visit at psychneurocoglab.com. Please do not disclose any personal or sensitive information via email.

Post expires: 3/1/2023

The purpose of this study is to investigate the relationship between aging processes and PTSD, which may help identify novel therapeutic targets to promote healthier aging trajectories for PTSD patients. Chronic PTSD increases mortality risk from medical diseases, promotes aging-associated syndromes such as frailty, and is linked to faster cognitive decline in older adults. One strong possibility is that PTSD leads to these adverse health outcomes by accelerating biological aging in the brain and body.

Participants will be asked to attend a total of 3 visits consisting of: an evaluation, an MRI, and a day of neuropsychological testing.

To participate, individuals must be 50 years or older. This study is enrolling healthy control volunteers.

To compensate for the time required for the eligibility evaluation, we offer $50 cash upon completion. Additionally, you will be paid $300 if you complete all procedures in this study, including the two additional study visits. Payment will take place in the form of a check.

A person to contact, and a website for more general information.

Nicolas Cimino at 646-774-8655 or nicolas.cimino@nyspi.columbia.edu

https://recruit.cumc.columbia.edu/clinical_trial/1649

Post expires: October 2022

Treatment-resistant depression (TRD) is a major health problem for the growing population of older adults. Unfortunately, there is a lack of evidence-based treatments that establish the benefits vs. risk of medication in this patient population. The purpose of this research study is to find out which antidepressants work best in individuals over the age of 60 who did not respond or were intolerant to at least two antidepressant medications. The study offers treatment with FDA approved medications: aripiprazole, bupropion, lithium, and nortriptyline.

Participants will be prescribed medication by the study psychiatrist. Progress will be monitored through biweekly phone calls or visits with the study staff. Participants will be asked to complete neuropsychological assessments, answer questions about their mood, and report medication tolerance.

To participate, individuals must be 60 years or older.

Subjects are paid $50 for completing initial evaluation. If found eligible and enrolled into the study, subjects receive $75 at the baseline visit, $75 at the end of 10-weeks of treatment, and $25 at each of 3 follow up visits after completing the initial 10 weeks of acute treatment.

A person to contact, and a website for more general information.
Johana Alvarez at 646-774-8664 (johana.alvarez@nyspi.columbia.edu) or Esteban Ceballos for service in Spanish at 646-774-8670 (esteban.ceballos@nyspi.columbia.edu)

https://recruit.cumc.columbia.edu/clinical_trial/953

Post expires: October 2022

The purpose of this 8-week study is to evaluate the effectiveness of a medication called tianeptine for treating depression in people whose symptoms have not responded to two prior treatments.

To participate, individuals must be between the ages of 21-50 and must have tried at least two antidepressant medications without complete success. Individuals can receive up to $1000 over the course of participation.

For more information, contact Sara Fernandez at 646-774-8698 or sara.fernandez@nyspi.columbia.edu.

Go here to apply: https://recruit.cumc.columbia.edu/clinical_trial/2008

This post expires in 2023.

The purpose of this study is to determine if taking a pill of estradiol (a form of estrogen) together with prolonged exposure (PE) therapy can improve this treatment outcome in women with Post-Traumatic Stress Disorder (PTSD). Prolonged Exposure (PE) therapy is a validated, evidence-based talk therapy that focuses on helping individuals with PTSD process memories of the trauma. Based on previous findings that the hormone estrogen facilitates people learning not to fear things they had feared before, we want to supplement prolonged exposure therapy with an estradiol pill given before each therapy session. Participants will be randomly assigned to either take estrogen or a placebo (which looks just like the estrogen pill but contains no medicine). Participants will not know which pill they are taking. As part of this study, participants will be asked to go through two separate fMRI scans, one before prolonged exposure therapy treatment and one after. This machine is routinely used by scientists to study the brain and does not use any radiation (x-rays).

The study involves 12 visits to our lab, which is located in midtown east Manhattan, over the course of a 6-9-week period. These visits can be broken down into 2 experimental days, 6 prolonged exposure therapy sessions, and 2 more experimental days. Participation in this study requires 12 visits over six weeks. Six of these visits will be therapy sessions. The other 6 days include assessment visits and going through an emotional learning and memory task before and after therapy. Participants will undergo a fear conditioning procedure that involves receiving an annoying but not painful, half-second electric current applied to the fingers. This procedure will be conducted during two consecutive days. The second day will be conducted in an fMRI scanner. Participants will be paid for their time. Blood samples will be gathered at different time points of the study. There will also be follow-up visits at 3 months and 6 months.

Eligibility criteria: Females between the ages of 18-45 who are taking an oral contraceptive (i.e., birth control)

Is the study therapeutic? Yes – participants will receive free Prolonged Exposure therapy no matter which study arm they are assigned to (i.e., placebo vs estradiol pill).

Is the study funded? Yes, this study is funded by the National Institute of Mental Health (NIMH)

Who will be conducting the study? The study is being conducted at two different sites: Dr. Mohammed Milad is conducting the study within the Department of Psychiatry at NYU Langone Health, and Dr. Edna Foa is conducting the study within the Department of Psychiatry at the University of Pennsylvania Perelman School of Medicine.

Will subjects be paid? Yes – The total compensation for all completed parts will be 480 dollars. Participants will receive 10 dollars for each study visit from visits 1-11 to help defray costs of travel and time. Participants will then receive 270 dollars upon completion of visit 12.

Participants will receive 50 dollars at each remaining follow-up visit. Participants who drop out of the study will be paid for the visits they attended.

Contact information: For more information regarding the study, you can call 1-888-44-WORRY or email Behavioralneuroscience@nyulangone.org. You can also complete the online pre-screening by following this link: https://is.gd/NYU_PTSD_STUDY and a research coordinator will reach out to you with further information about the study.

Post Expiration: The study will be recruiting until June 2023

This study is an anonymous online survey for adults with a mental health condition and their family members/caregivers. The goal of the survey is to understand how much people know about the physical health risks related to mental health conditions and treatments. The survey will ask questions about the participant’s knowledge of physical health and about the care they have received from health care providers. This study will help health care providers improve the ways they educate and support people with mental health conditions.

The study is being conducted by researchers at the University of Massachusetts Lowell and McLean Hospital. The survey takes 15-20 minutes to complete.

Participants may be eligible for this study if they are:

• Aged 18 or older
• Have a mental health condition, or are the family member/ caregiver of a person with a mental health condition

The survey is available online. To access the survey please use the following link: https://umasslowell.co1.qualtrics.com/jfe/form/SV_80MfUYLoMqduzvD

HOW DO I LEARN MORE?
If you have questions or would like more information, please contact the researchers at (978) 934-4471 or Margaret_Knight@uml.edu.

Description: Researchers at the Icahn School of Medicine at Mount Sinai are looking for adults with Panic Disorder, Generalized Anxiety Disorder and/or Post-traumatic Stress Disorder to participate in a brain imaging study. Study investigators hope to learn how the brain is affected by stress and anxiety using new brain imaging technology.

You may be eligible to participate in this study if you:

• Are 18-55 years old
• Have Panic Disorder, Generalized Anxiety Disorder (GAD) or Post-Traumatic Stress Disorder (PTSD)

Participation in this research study includes a study screen and brain scan using magnetic resonance imaging (MRI), which can be done over 1-3 visits. Each study visit is expected to last approximately 2 – 5 hours in length. Subjects will be compensated for their participation.

Contact: If you are interested in participating, please take our online pre-screen at https://redcap.mountsinai.org/redcap/surveys/?s=VionGV8Bjh.

This study will expire in January 2024.